|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
FI933755L
(fi)
|
1991-02-27 |
1993-08-26 |
Pfizer |
Foerfarande foer framstaellning av trans-piperidin-2,5-dikarboxylater
|
|
CA2192725C
(en)
|
1995-12-28 |
2004-04-20 |
Kenji Tsujihara |
Camptothecin derivatives
|
|
US7365205B2
(en)
|
2001-06-20 |
2008-04-29 |
Daiichi Sankyo Company, Limited |
Diamine derivatives
|
|
WO2005056606A2
(en)
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Optimized antibodies that target the epidermal growth factor receptor
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
WO2009011285A1
(ja)
|
2007-07-13 |
2009-01-22 |
Taisho Pharmaceutical Co., Ltd. |
ヘテロアリールベンゼン化合物
|
|
CA2721093A1
(en)
|
2008-04-11 |
2009-10-15 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
|
UA104868C2
(uk)
|
2008-08-15 |
2014-03-25 |
Меррімак Фармасьютікалз, Інк. |
Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
|
|
CN102282168A
(zh)
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
|
NZ596711A
(en)
|
2009-05-01 |
2013-11-29 |
|
Dual variable domain immunoglobulins and uses thereof
|
|
UY32808A
(es)
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
|
KR20120060877A
(ko)
|
2009-09-01 |
2012-06-12 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
TW201122101A
(en)
|
2009-10-28 |
2011-07-01 |
Facet Biotech Corp |
Anti-EGFR antibodies and their uses
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9051370B2
(en)
|
2010-08-10 |
2015-06-09 |
Glycotope Gmbh |
Humanized EGFR antibodies
|
|
US20120263722A1
(en)
|
2010-11-04 |
2012-10-18 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
WO2012088290A2
(en)
|
2010-12-22 |
2012-06-28 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
|
EP2678359A4
(en)
|
2011-02-24 |
2015-01-28 |
Merrimack Pharmaceuticals Inc |
COMBINATION THERAPIES WITH ANTI-ERBB3 MEDIUM
|
|
SG192775A1
(en)
|
2011-03-15 |
2013-09-30 |
Merrimack Pharmaceuticals Inc |
Overcoming resistance to erbb pathway inhibitors
|
|
BR112014016299A8
(pt)
|
2011-12-30 |
2017-07-04 |
Abbvie Inc |
imunoglobulinas de domínio variável e usos das mesmas
|
|
KR101721678B1
(ko)
|
2012-03-08 |
2017-03-31 |
할로자임, 아이엔씨 |
조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
|
|
CN104540518A
(zh)
|
2012-04-27 |
2015-04-22 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
CA2873111A1
(en)
|
2012-05-11 |
2013-11-14 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
|
|
ES2690315T3
(es)
|
2012-06-15 |
2018-11-20 |
Mitsubishi Tanabe Pharma Corporation |
Compuestos de imidazol y triazol como inhibidores de DGAT-1
|
|
JP2015527366A
(ja)
|
2012-08-20 |
2015-09-17 |
グリックニック インコーポレイテッド |
抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
|
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
US20150239977A1
(en)
|
2012-09-27 |
2015-08-27 |
Massachusetts Institute Of Technology |
Cd20- and egfr-binding proteins with enhanced stability
|
|
DK2907824T3
(en)
|
2012-10-11 |
2018-07-23 |
Daiichi Sankyo Co Ltd |
ANTIBODY-drug conjugate
|
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
|
CA3081073C
(en)
|
2013-03-12 |
2023-09-12 |
Biocon Ltd. |
Fusion immunomodulatory proteins and methods for making same
|
|
AU2014227638A1
(en)
|
2013-03-15 |
2015-09-17 |
Merck Patent Gmbh |
Tetravalent bispecific antibodies
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
US9879081B2
(en)
|
2013-06-25 |
2018-01-30 |
Samsung Electronics Co., Ltd. |
Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
|
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
MX2016003256A
(es)
|
2013-09-12 |
2016-06-07 |
Halozyme Inc |
Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
CN110627907B
(zh)
|
2013-11-04 |
2024-03-29 |
艾科诺斯科技股份有限公司 |
重靶向t细胞的异源二聚免疫球蛋白的产生
|
|
AU2014348552A1
(en)
|
2013-11-13 |
2016-06-02 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
|
|
LT3424955T
(lt)
|
2013-12-25 |
2025-06-25 |
Daiichi Sankyo Company, Limited |
Anti-trop2 antikūno ir vaisto konjugato gamybos būdas
|
|
SI3466976T1
(sl)
|
2014-01-31 |
2021-12-31 |
Daiichi Sankyo Company, Limited |
Anti-her2 konjugat protitelesa-zdravila
|
|
SG10202001468UA
(en)
*
|
2014-02-17 |
2020-04-29 |
Seattle Genetics Inc |
Hydrophilic antibody-drug conjugates
|
|
JP6612738B2
(ja)
*
|
2014-04-10 |
2019-11-27 |
第一三共株式会社 |
抗ｈｅｒ２抗体−薬物コンジュゲート
|
|
KR102399277B1
(ko)
|
2014-04-10 |
2022-05-18 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
JP5924795B2
(ja)
|
2014-06-13 |
2016-05-25 |
テンボロン オイ |
複合体
|
|
CN106470697B
(zh)
|
2014-09-16 |
2019-10-25 |
兴盟生物医药(苏州)有限公司 |
抗egfr抗体以及其用途
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
SG11201704741PA
(en)
*
|
2014-12-22 |
2017-07-28 |
Systimmune Inc |
Bispecific tetravalent antibodies and methods of makiing and using thereof
|
|
CN105820248A
(zh)
|
2015-01-07 |
2016-08-03 |
上海张江生物技术有限公司 |
一种新型抗egfr单克隆抗体的制备方法及应用
|
|
KR101770559B1
(ko)
|
2015-04-23 |
2017-08-24 |
신일제약주식회사 |
EGFR에 특이적으로 결합하는 Fab 단편
|
|
WO2016196682A1
(en)
|
2015-06-01 |
2016-12-08 |
Immunexcite, Inc. |
β-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES
|
|
WO2016210447A1
(en)
|
2015-06-26 |
2016-12-29 |
University Of Southern California |
Masking chimeric antigen receptor t cells for tumor-specific activation
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US20170247458A1
(en)
|
2016-01-10 |
2017-08-31 |
Sorrento Therapeutics, Inc. |
Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR
|
|
AU2017236431A1
(en)
|
2016-03-24 |
2018-09-27 |
Bayer Pharma Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
CN109563166B
(zh)
|
2016-04-28 |
2022-12-20 |
拜奥穆尼克斯制药 |
靶向egfr和her2的双特异性抗体
|
|
US11649291B2
(en)
|
2016-05-24 |
2023-05-16 |
Insmed Incorporated |
Antibodies and methods of making same
|
|
WO2018026742A1
(en)
|
2016-08-01 |
2018-02-08 |
Askgene Pharma Inc. |
Novel antibody-albumin-drug conjugates (aadc) and methods for using them
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
BR112019011794A2
(pt)
|
2016-12-12 |
2019-10-29 |
Daiichi Sankyo Co Ltd |
composição farmacêutica, e, método terapêutico.
|
|
CA3047491A1
(en)
|
2016-12-21 |
2018-06-28 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
GB201705686D0
(en)
|
2017-04-07 |
2017-05-24 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
CN108948195B
(zh)
|
2017-05-23 |
2022-05-31 |
胡毅 |
一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
|
|
CN108948206B
(zh)
|
2017-05-23 |
2022-08-23 |
赵磊 |
一种抗egfr/pd-1双靶向抗体、其制备方法及用途
|
|
JP2020521759A
(ja)
|
2017-05-26 |
2020-07-27 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ
|
|
EP3638700B8
(en)
|
2017-06-14 |
2024-09-04 |
Shihuida Pharmaceutical Group (Jilin) Co., Ltd., a China corporation |
Proteinaceous heterodimer and use thereof
|
|
US12605458B2
(en)
|
2017-06-19 |
2026-04-21 |
Systimmune, Inc. |
Antibody-drug conjugate having acidic self-stabilization junction
|
|
CN109306010B
(zh)
|
2017-07-26 |
2022-07-19 |
石家庄以岭药业股份有限公司 |
表皮生长因子受体抗体及其用途
|
|
AU2018318698A1
(en)
|
2017-08-16 |
2020-02-20 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16, and EGFR, HLA-E CCR4, or PD-L1
|
|
CN109106951A
(zh)
*
|
2017-08-18 |
2019-01-01 |
四川百利药业有限责任公司 |
一种喜树碱-抗体偶联物
|
|
ES3057444T3
(en)
|
2017-08-31 |
2026-03-02 |
Daiichi Sankyo Co Ltd |
Improved method for producing antibody-drug conjugate
|
|
BR112020003466B1
(pt)
|
2017-08-31 |
2023-12-12 |
Daiichi Sankyo Company, Limited |
Métodos de produção de composto, e, composto
|
|
EP3457139A1
(en)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
|
JP2020536967A
(ja)
|
2017-10-12 |
2020-12-17 |
イミュノウェイク インコーポレイテッド |
Ｖｅｇｆｒ−抗体軽鎖融合タンパク質
|
|
CN108220244A
(zh)
|
2018-01-18 |
2018-06-29 |
东北农业大学 |
一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
|
|
US10654944B2
(en)
|
2018-04-10 |
2020-05-19 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
US12168691B2
(en)
|
2018-05-31 |
2024-12-17 |
Board Of Regents, The University Of Texas System |
VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
|
|
EP3810624A4
(en)
|
2018-06-22 |
2022-07-06 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
EP3866924A4
(en)
|
2018-06-29 |
2022-07-06 |
Krystal Biotech, Inc. |
COMPOSITIONS AND METHODS OF ANTIBODY DELIVERY
|
|
WO2020063676A1
(zh)
|
2018-09-26 |
2020-04-02 |
江苏恒瑞医药股份有限公司 |
依喜替康类似物的配体-药物偶联物及其制备方法和应用
|
|
CN112543771B
(zh)
|
2018-09-30 |
2023-04-11 |
江苏豪森药业集团有限公司 |
抗b7h3抗体-依喜替康类似物偶联物及其医药用途
|
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
GB201816553D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
CA3118397A1
(en)
|
2018-11-01 |
2020-05-07 |
Shandong Newtime Pharmaceutical Co., Ltd. |
Bispecific antibody targeting cd3 and bcma, and uses thereof
|
|
CN111196855B
(zh)
|
2018-11-19 |
2022-11-15 |
三生国健药业（上海）股份有限公司 |
抗egfr/pd-1双特异性抗体
|
|
WO2020113164A1
(en)
|
2018-11-30 |
2020-06-04 |
Memorial Sloan Kettering Cancer Center |
Heterodimeric tetravalency and specificity antibody compositions and uses thereof
|
|
WO2020118605A1
(zh)
|
2018-12-13 |
2020-06-18 |
丁邦 |
抗体-肿瘤坏死因子α融合蛋白及其制法和应用
|
|
EP3898681A2
(en)
|
2018-12-17 |
2021-10-27 |
Alligator Bioscience AB |
Polypeptides
|
|
JP7506607B2
(ja)
|
2018-12-28 |
2024-06-26 |
協和キリン株式会社 |
ＴｆＲに結合するバイスペシフィック抗体
|
|
CN111689980A
(zh)
*
|
2019-05-26 |
2020-09-22 |
四川百利药业有限责任公司 |
一种喜树碱药物及其抗体偶联物
|
|
MX2021014960A
(es)
|
2019-06-06 |
2022-03-04 |
Shanghai Hansoh Biomedical Co Ltd |
Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo.
|
|
CN110256583B
(zh)
|
2019-07-11 |
2022-05-20 |
中国科学院生物物理研究所 |
一种il-2突变体与抗体的融合蛋白及其应用
|
|
US12168690B2
(en)
|
2019-07-26 |
2024-12-17 |
Abl Bio Inc. |
Anti-EGFR/anti-4-1BB bispecific antibody
|
|
CN110669132B
(zh)
|
2019-08-19 |
2023-03-31 |
天津大学前沿技术研究院 |
一种提高IgG1抗体产量的方法
|
|
CN112125915A
(zh)
*
|
2019-09-18 |
2020-12-25 |
四川百利药业有限责任公司 |
一种喜树碱衍生物及其偶联物
|
|
CN114616031A
(zh)
|
2019-09-19 |
2022-06-10 |
Igm生物科学股份有限公司 |
对靶标密度高的细胞的选择性增强的多聚体抗体
|
|
AU2020402006A1
(en)
|
2019-12-12 |
2022-07-07 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
|
|
AU2020410460A1
(en)
|
2019-12-16 |
2022-06-16 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-CEA antibody-exatecan analog conjugate and pharmaceutical use thereof
|
|
MX2022008474A
(es)
|
2020-01-22 |
2022-08-02 |
Jiangsu Hengrui Medicine Co |
Conjugado de anticuerpo anti-trop-2-analogo de exatecan y uso medico del mismo.
|
|
CN115485300A
(zh)
|
2020-02-26 |
2022-12-16 |
索伦托药业有限公司 |
具有通用掩蔽部分的可活化的抗原结合蛋白
|
|
CN113388631B
(zh)
|
2020-03-12 |
2022-08-09 |
天津大学 |
一种高产IgG1的重组菌及构建方法
|
|
CN115298220B
(zh)
|
2020-03-24 |
2024-12-20 |
上海翰森生物医药科技有限公司 |
抗体-药物偶联物及其医药用途
|
|
CA3177279A1
(en)
|
2020-03-25 |
2021-09-30 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-psma antibody-exatecan analogue conjugate and medical use thereof
|
|
JP7689979B2
(ja)
|
2020-03-25 |
2025-06-09 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗体薬物複合体を含む医薬組成物及びその使用
|
|
BR112022019042A2
(pt)
|
2020-03-25 |
2022-11-01 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Método de preparação para conjugado anticorpo-fármaco
|
|
WO2021190586A1
(zh)
|
2020-03-25 |
2021-09-30 |
江苏恒瑞医药股份有限公司 |
B7h3抗体-依喜替康类似物偶联物及其医药用途
|
|
CN115279781B
(zh)
|
2020-03-26 |
2025-05-09 |
上海翰森生物医药科技有限公司 |
抗体药物偶联物及其医药用途
|
|
US10994021B1
(en)
|
2020-04-11 |
2021-05-04 |
Bliss Biopharmaceutical (Hangzhou) Co., Ltd. |
Tetravalent antibody-drug conjugates and use thereof
|
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业（上海）股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
|
CN113754771A
(zh)
|
2020-06-02 |
2021-12-07 |
三生国健药业（上海）股份有限公司 |
一种抗pdl1×egfr的双特异性抗体
|
|
CA3186295A1
(en)
*
|
2020-06-08 |
2021-12-16 |
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. |
Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
|
|
CN111848806B
(zh)
|
2020-06-18 |
2022-06-10 |
广东安普泽生物医药股份有限公司 |
Egfr-cd3双功能抗体及其应用
|
|
MX2023001163A
(es)
|
2020-07-27 |
2023-02-22 |
Tuojie Biotech Shanghai Co Ltd |
Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo.
|
|
JP7780953B2
(ja)
|
2020-09-15 |
2025-12-05 |
バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． |
カンプトテシン類医薬品及びその抗体複合体
|
|
KR20230079096A
(ko)
|
2020-09-30 |
2023-06-05 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
항체-약물 접합체를 포함하는 약제학적 조성물 및 약제학적 조성물의 용도
|
|
US20250276078A1
(en)
*
|
2020-10-12 |
2025-09-04 |
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. |
Camptothecin Derivative And Ligand-drug Conjugate Thereof
|
|
EP4227309A4
(en)
*
|
2020-10-12 |
2024-11-27 |
Sichuan Baili Pharmaceutical Co. Ltd. |
DEUTERATED CAMPTOTHECIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF
|
|
CN116133694B
(zh)
|
2020-10-14 |
2026-03-06 |
苏州盛迪亚生物医药有限公司 |
抗her3抗体和抗her3抗体药物偶联物及其医药用途
|
|
WO2022099762A1
(zh)
|
2020-11-12 |
2022-05-19 |
博瑞生物医药（苏州）股份有限公司 |
一种抗体偶联物中间体及其制备方法
|
|
CN114569739A
(zh)
|
2020-12-01 |
2022-06-03 |
正大天晴药业集团股份有限公司 |
抗体药物偶联物
|
|
KR20250120438A
(ko)
|
2021-02-05 |
2025-08-08 |
쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 |
캄프토테신 화합물, 그의 제조방법 및 그의 응용
|
|
WO2022166719A1
(zh)
|
2021-02-08 |
2022-08-11 |
四川百利药业有限责任公司 |
一种ca4衍生物及其配体-药物偶联物
|
|
TW202300148A
(zh)
|
2021-03-17 |
2023-01-01 |
大陸商江蘇恒瑞醫藥股份有限公司 |
喜樹鹼衍生物的製備方法
|
|
CN115192732B
(zh)
|
2021-04-01 |
2025-02-18 |
成都百利多特生物药业有限责任公司 |
一种dna毒性二聚体化合物及其偶联物
|
|
US20240269307A1
(en)
|
2021-04-26 |
2024-08-15 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal use thereof
|
|
CN113816969B
(zh)
|
2021-04-30 |
2024-01-16 |
联宁（苏州）生物制药有限公司 |
依喜替康类化合物、其抗体药物偶联物及其应用
|
|
BR112023023276A2
(pt)
|
2021-05-07 |
2024-01-30 |
Alx Oncology Inc |
Derivados de exatecan e conjugados anticorpo-fármaco destes
|
|
CA3224741A1
(en)
|
2021-06-25 |
2022-12-29 |
Coherent Biopharma (Suzhou), Limited |
Ligand-drug conjugate and use thereof
|
|
TW202320858A
(zh)
|
2021-07-19 |
2023-06-01 |
美商薩諾管理公司 |
免疫接合物及方法
|
|
CN118139891A
(zh)
|
2021-09-23 |
2024-06-04 |
上海翰森生物医药科技有限公司 |
抗体药物偶联物及其制备方法和医药用途
|
|
CN115850291B
(zh)
|
2021-09-24 |
2024-11-15 |
石药集团巨石生物制药有限公司 |
喜树碱衍生物及其用途
|
|
US11814394B2
(en)
|
2021-11-16 |
2023-11-14 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Exatecan derivatives, linker-payloads, and conjugates and thereof
|
|
AU2022389555A1
(en)
|
2021-11-17 |
2024-07-04 |
CSPC Megalith Biopharmaceutical Co., Ltd. |
Antibody-drug conjugate and use thereof
|
|
CN116212044A
(zh)
|
2021-12-03 |
2023-06-06 |
成都百利多特生物药业有限责任公司 |
抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
|
|
CN118414339A
(zh)
|
2021-12-16 |
2024-07-30 |
迈威(上海)生物科技股份有限公司 |
一种喜树碱类化合物及其偶联物
|
|
CN118450907A
(zh)
|
2021-12-28 |
2024-08-06 |
百济神州有限公司 |
抗体药物结合物
|